United States· US:73604-914_11e22c54-9b9a-4f9f-8680-cb7327511a23
Arcalyst
A rilonacept product containing rilonacept, registered in United States by Kiniksa Pharmaceuticals (UK), Ltd.. The same ATC class is registered in 2 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rilonacept is registered in 2 of 19 countries.
Countries holding a registration under ATC L04AC04 (rilonacept), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Rilonacept · ATC L04AC04
2 / 19 countries
- Finlandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RILONACEPT
- Manufacturer
- Kiniksa Pharmaceuticals (UK), Ltd.
- Country
- United States (US)
- ATC code
- L04AC04
- ATC class
- Rilonacept
- Defined daily dose
- 23 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1173604914011 VIAL, SINGLE-USE in 1 CARTON (73604-914-01) / 2 mL in 1 VIAL, SINGLE-USE
- ndc1173604914044 VIAL, SINGLE-USE in 1 CARTON (73604-914-04) / 2 mL in 1 VIAL, SINGLE-USE
- ndc1173604-914-01
- ndc1173604-914-04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
376 interactions on record for rilonacept.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rilonacept · interactions on record
376 records
- 30 severe
- 339 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rilonacept in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f174df99-1c9a-4881-97c0-e55bf6cabbe7 GET /v1/drugs/f174df99-1c9a-4881-97c0-e55bf6cabbe7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "160",
"substance": "RILONACEPT",
"productndc": "73604-914",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/2mL",
"application_number": "BLA125249",
"marketing_category": "BLA"
}See everything about rilonacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.